Free Trial
NASDAQ:LTRN

Lantern Pharma (LTRN) Stock Price, News & Analysis

Lantern Pharma logo
$3.31
+0.19 (+6.09%)
(As of 11/1/2024 ET)

About Lantern Pharma Stock (NASDAQ:LTRN)

Key Stats

Today's Range
$3.05
$3.31
50-Day Range
$3.13
$4.64
52-Week Range
$2.53
$11.99
Volume
20,492 shs
Average Volume
136,467 shs
Market Capitalization
$35.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Lantern Pharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
18th Percentile Overall Score

LTRN MarketRank™: 

Lantern Pharma scored higher than 18% of companies evaluated by MarketBeat, and ranked 906th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Lantern Pharma are expected to grow in the coming year, from ($2.12) to ($2.02) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lantern Pharma is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lantern Pharma is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lantern Pharma has a P/B Ratio of 0.86. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Lantern Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    2.21% of the float of Lantern Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Lantern Pharma has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lantern Pharma has recently decreased by 6.89%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Lantern Pharma does not currently pay a dividend.

  • Dividend Growth

    Lantern Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.21% of the float of Lantern Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Lantern Pharma has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lantern Pharma has recently decreased by 6.89%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Lantern Pharma has a news sentiment score of -0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Lantern Pharma this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for LTRN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Lantern Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lantern Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.31% of the stock of Lantern Pharma is held by insiders.

  • Percentage Held by Institutions

    Only 28.62% of the stock of Lantern Pharma is held by institutions.

  • Read more about Lantern Pharma's insider trading history.
Receive LTRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lantern Pharma and its competitors with MarketBeat's FREE daily newsletter.

LTRN Stock News Headlines

Sell NVDA Now?
Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.
See More Headlines

LTRN Stock Analysis - Frequently Asked Questions

Lantern Pharma's stock was trading at $4.28 at the beginning of 2024. Since then, LTRN stock has decreased by 24.1% and is now trading at $3.25.
View the best growth stocks for 2024 here
.

Lantern Pharma Inc. (NASDAQ:LTRN) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.09.

Lantern Pharma (LTRN) raised $26 million in an IPO on Thursday, June 11th 2020. The company issued 1,600,000 shares at $15.00-$17.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Dougherty & Company and Paulson Investment Company were co-managers.

Shares of LTRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lantern Pharma investors own include NVIDIA (NVDA), Tesla (TSLA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Intel (INTC), Meta Platforms (META) and NIO (NIO).

Company Calendar

Last Earnings
8/08/2024
Today
11/02/2024
Next Earnings (Confirmed)
11/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LTRN
Fax
N/A
Employees
20
Year Founded
2013

Profitability

Net Income
$-15,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.76 per share

Miscellaneous

Free Float
9,978,000
Market Cap
$35.00 million
Optionable
Optionable
Beta
1.55

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:LTRN) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners